Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799598 | 1.00 | KMT2A (0.69) | KMT2APLA2G4BNR4A2PRSS1NR1H4 | |
| SCHEMBL4509654 | 0.93 | KMT2A (0.77) | KMT2APLA2G4BNR4A2PRSS1NR1H4 | |
| SCHEMBL9803295 | 0.91 | KMT2A (0.80) | KMT2APLA2G4BNR4A2PRSS1NR1H4 | |
| SCHEMBL8517907 | 0.90 | KMT2A (0.73) | KMT2APLA2G4BNR4A2NR1H4AKR1C3 | |
| SCHEMBL30167982 | 0.88 | KMT2A (0.80) | KMT2APLA2G4BNR4A2PRSS1NR1H4 | |
| SCHEMBL10787479 | 0.88 | KMT2A (0.80) | KMT2APLA2G4BNR4A2PRSS1NR1H4 | |
| SCHEMBL201793 | 0.87 | PRSS1 (0.62) | KMT2APRSS1SMPD1 | |
| SCHEMBL9402647 | 0.86 | KMT2A (0.73) | KMT2APLA2G4BNR4A2PRSS1NR1H4 | |
| SCHEMBL2887568 | 0.85 | KMT2A (0.82) | KMT2APLA2G4BNR1H4SMPD1 | |
| SCHEMBL8086388 | 0.85 | KMT2A (0.82) | KMT2APLA2G4BNR1H4SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1602354-B1 | Use of polyglutamic acid or its salts | MEIJI SEIKA KAISHA (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1604647-B1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | CHISSO CORP (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060018867-A1 | Cosmetic composition and production thereof | ICHIMARU PHARCOS CO., LTD | 2006-01-26 | — | — | US | disclosed |
| EP-1604647-A1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | Ichimaru Pharcos Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
| WO-1996017589-A1 | METHOD OF SMOOTHING OR REMOVING WRINKLES AND METHOD OF STIMULATING COLLAGEN SYNTHESIS | KAO CORPORATION (JP) | 1996-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | KMT2A 998/4885PLA2G4B 4685/4885NR4A2 4434/4885 |
| US-20060018867-A1 | Cosmetic composition and production thereof | CUTA, PARG, TYR | KMT2A 847/4885PLA2G4B 1586/4885NR4A2 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.